KIF6 and Hermansky-Pudlak syndrome: In the HPS placebo patients have been intensively treated with 40 mg simvastatin for 6 weeks prior to randomization which substantially reduced LDL-C levels and according to Ference et al. [18] could attenuate risk associated with KIF6 and therefore explain the lack of a differential response to statin therapy in those with KIF6 genotype.